Indications: Niraparib is prescribed for the following condition:

• Maintenance treatment of advanced ovarian cancer in patients who have responded to platinum-based chemotherapy.

Pharmacology: Niraparib functions as a PARP inhibitor, hindering PARP enzymes responsible for DNA repair. This inhibition prevents cancer cells from repairing their DNA, leading to cell death.

Dosage and Administration: The typical dosage is 300 mg orally once daily. Adjustments may be made for Niraparib Tosylate Monohydrate equivalent to Niraparib 100 mg. It can be taken with or without food.

Interactions: Niraparib may interact with other medications, so it’s essential to disclose all medications, including over-the-counter drugs, vitamins, and herbal supplements, to healthcare providers.

Side Effects: Common side effects include nausea, vomiting, fatigue, anemia, reduced appetite, diarrhea, and abdominal pain. More severe effects may include bone marrow suppression and an elevated risk of specific cancers.

Precautions and Warnings: Niraparib can lead to bone marrow suppression, necessitating regular blood tests to monitor blood cell counts. Patients should also be monitored for signs of new cancers.

Overdose Effects: In the event of an overdose, supportive measures are necessary. There is no specific antidote, and treatment focuses on managing symptoms.